The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2014

Filed:

May. 07, 2009
Applicants:

Daniel Obrecht, Bättwil, CH;

Frank Gombert, Basel, CH;

Alexander Lederer, Basel, CH;

Barbara Romagnoli, Allschwil, CH;

Christian Bisang, Basel, CH;

Inventors:

Daniel Obrecht, Bättwil, CH;

Frank Gombert, Basel, CH;

Alexander Lederer, Basel, CH;

Barbara Romagnoli, Allschwil, CH;

Christian Bisang, Basel, CH;

Assignee:

Polyphor AG, Allschwil, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); C07K 7/54 (2006.01); A61P 35/00 (2006.01); C07K 7/08 (2006.01); C07K 7/02 (2006.01);
U.S. Cl.
CPC ...
C07K 7/02 (2013.01); C07K 7/08 (2013.01);
Abstract

β-Hairpin peptidomimetics of the general formula Cyclo(-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Arg-Tyr-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-), disulfide bond between Cysand Cys11, and pharmaceutically acceptable salts thereof, with Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaa, Xaaand Xaabeing amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptides can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.


Find Patent Forward Citations

Loading…